Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension

Hypertension

Volumn 45, Issue 2, 2005, Pages 193-197

  Hermann, Matthias ^a,b   Shaw, Sidney ^c   Kiss, Eva ^d   Camici, Giovanni ^a   Bühler, Nico ^a   Chenevard, Remy ^b   Lüscher, Thomas F ^b   Gröne, Hermann J ^d   Ruschitzka, Frank ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Hypertension; Kidney; Proteinuria

Indexed keywords

C REACTIVE PROTEIN; CELECOXIB; CYCLOOXYGENASE 2; DICLOFENAC; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PLACEBO; ROFECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; GENE EXPRESSION; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HYPERTENSION; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY INJURY; MACROPHAGE; MALE; MESANGIAL SCLEROSIS; MESANGIOLYSIS; MESANGIUM; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALT INTAKE; SCLEROSIS;

ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; C-REACTIVE PROTEIN; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; HEMODYNAMIC PROCESSES; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY CORTEX; KIDNEY GLOMERULUS; LACTONES; MONOCYTES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, INBRED DAHL; RNA, MESSENGER; SODIUM CHLORIDE; SULFONAMIDES; SULFONES;

EID: 13144307053     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000153053.82032.bf     Document Type: Article

References (23)

1. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
2. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004;43:525-530.
3. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension. 2002;39:929-934.
4. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
5. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068-2073.
6. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004;44:140-145.
7. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751-1756.
8. Quaschning T, D'Uscio LV, Shaw S, Grone HJ, Ruschitzka F, Luscher TF. Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension. J Am Soc Nephrol. 2001;12:2280-2287.
9. Hermann M, Camici G, Fratton A, Hurlimann D, Tanner FC, Hellermann JP, Fiedler M, Thiery J, Neidhart M, Gay RE, Gay S, Luscher TF, Ruschitzka F. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation. 2003;108:2308-2311.
10. Kiss E, Adams J, Grone HJ, Wagner J. Isotretinoin ameliorates renal damage in experimental acute renal allograft rejection. Transplantation. 2003;76:480-489.
11. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, Luscher TF. Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension. 1997;30:817-824.
12. Fogo AB. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl. 2000;75:S15-S21.
13. Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 1999;33:389-395.
14. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
15. Jabs WJ, Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, Fricke L, Steinhoff J. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol. 2003;33:152-161.
16. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
17. Kinnula VL, Chang LY, Ho YS, Crapo JD. Hydrogen peroxide release from alveolar macrophages and alveolar type II cells during adaptation to hyperoxia in vivo. Exp Lung Res. 1992;18:655-673.
18. White WB. Hypertension associated with therapies to treat arthritis and pain. Hypertension. 2004;44:123-124.
19. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol. 2004;68:341-350.
20. Yang HM, Kim HS, Park KW, You HJ, Jeon SI, Youn SW, Kim SH, Oh BH, Lee MM, Park YB, Walsh K. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation. 2004;110:301-308.
21. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation. 2002;106:167-169.
22. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum. 2002;47:349-355.
23. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997;40:1347-1365.